启明医疗-B2023中期报告

4 5 26 55 57 59 61 64 1. 2. I. TPVRVenusP-ValveVenusP-ValveFDAIDECardiovalveVenus-Vitae, Venus-PowerX TAVRTPVRTAVRVenus-VitaeVenus-PowerXTMVRTTVRCardiovalveG SheathTAV0TAVRLiwen RF(RDN) VenusA-TAVR TAVRVenusA-ValveVenusA-PlusVenusA-ProVenusA-ValveNMPANMPATAVRVenusA-PlusNMPATAVR VenusA-ProVenusA-PlusVenusA-ProNMPATAVR VenusA21CIT 2023VenusA-Valve80%VenusA-Valve9China ValveHangzhouVenusA-PlusVenusA-PlusVenusA-PlusTAVRVenusA VenusA229.8196.616.9% VenusP-ValveTPVR (TPVR)VenusP-ValveCE MDR(RVOT)TPVRCE MDRIII VenusP-ValveNMPA≥3+TPVRVenusP-ValveVenusP-Valve30VenusP-Valve VenusP-ValveVenusP-Valve100%0%96.87%95.38%(NYHA)ClassIII7.69%1.67%Class I27.69%90%VenusP-Valve3.64%54.5%0%36.4%2.22%VenusP-Valve VenusP-ValvePROTEUSFDAIDEJapan-US Harmonization By Doing60 VenusP-Valve25.29.116.1 Venus-VitaeTAVR TAVRVenus-VitaeSMART-ALIGN Venus-VitaeVenus-EnduraSeadaptVenus-VitaeVenus-Vitae Venus-Vitae Venus-PowerXTAVR TAVRVenus-PowerXIMPACT Venus-PowerXVenus-Endura100%SeadaptVenus-PowerXVenus-PowerX Venus-PowerX CardiovalveTMVR/TTVR CardiovalveCardiovalve Cardiovalve55 mm95% CardiovalveCardiovalveTARGET CECardiovalve Cardiovalve Liwen RF HOCMLiwen RFLiwen RF67986.1%68/7923.36mm17.23mm26.2%72.86mmHg22.44mmHg69.2% Liwen RFHOCM Liwen RF144Liwen RF88%Liwen RFNMPA Liwen RF RDN HealiumRenalyRDN RDN TAVRVenus-VitaeVenus-PowerXVenusP-ValveCardiovalve Cardiovalve 294.7220.3 896397373235492314PCT31 3,500GMP20.64 ISO13485NMPAGMPFDAQSRMDRANVISARDCMDSAP ISO/IEC17025ISO13485MDRMDSAPBGMPCCNASMDSAP 260420TAVRTAVRTPVR 30Shakeel OsmanTAVR II. VenusA-ValveVenusA-ValveVenusP-ValveCE MDRNMPA 255.6210.021.7%VenusAVenusP-ValveVenusA89.9%93.7% 54.445.818.8% 164.222.5%201.278.2%78.7% 33.162.447.0% 157.9123.428.0% 294.7220.333.8% 77.954.742.4% 26.338.030.8% 1,276,312,000600,553,000 31.218.412.8 9.73.66.1 7.014.652% 4.16.7 1,453.21,879.422.7% 778.7796.013. 26.3%24.8% 1,473.01,976.925.5% 96.0(i)(ii)(iii)(iv) 648.9695.9–13. (i)(ii) 1,006 1,006862144 III. VenusP-Valve VenusP-ValveCardiovalveVenus-PowerXVenus-VitaeVenusP-ValveVenusP-Valve50 TAVR I. II. XV(a)XV78(b)352(c) (1)Horizon Binjiang LLC33,651,618HHorizon Binjiang LLC (2)32,644,302H20,261,919H1,208 •Adventure 03 Limited9,000,636HDinova Healthcare Gamma Fund (USD) L.P.Adventure 03 LimitedDinovaVenture Partners GP III, L.P.Dinova Healthcare Gamma Fund (USD) L.P.Dinova Capital LimitedDinova Venture Partners GP III, L.P.Xin NuoTong Investment LimitedDinova Capital LimitedXin Nuo TongInvestment LimitedAdventure 03 Limited •6,977,955H40% •DNA 01Hong Kong Limited2,056,615HDinova Healthcare Delta Fund (USD) L.P.DNA 01Hong Kong LimitedDinova Venture Partners GP IV, L.P.Dinova Healthcare Delta Fund (USD) L.P.Dinova Venture Capital LimitedDinova Venture Partners GP IV, L.P.Xin NuoTong Investment LimitedDinova Venture Capital Limited 40%Xin Nuo Tong Investment LimitedDNA 01HongKongLimited •1,687,358H66.67% •539,355H 1,208Jupiter Holdings LimitedMercuryHolding Limited (3)H441,011,443441,010,235H1,208 XVXV78352 III. 1818 IV. XV23336 (1)Horizon Binjiang LLC33,651,618HHorizon Binjiang LLC (2)Qiming Corporate GP III, Ltd.57,048,980H •Ming Zhi Investments (BVI) Limited40,018,283HMing Zhi Investments LimitedMing ZhiInvestments (BVI) LimitedQiming Venture Partners III, L.P.Ming ZhiInvestments Limited 96.94%Qiming GP III, L.P.Qiming Venture Partners III, L.PMing Zhi Investments (BVI) Limited •QM22 (BVI) Limited17,030,697HQM22 LimitedQM22 (BVI) LimitedQiming VenturePartners III Annex Fund, L.P.QM22 LimitedQiming GP III, L.P.QimingVenture Partners III Annex Fund, L.P.Qiming Corporate GP III, Ltd.QimingGP III, L.P.QM22 (BVI) Limited (3)Muheng Capital PartnersHong Kong Limited24,713,752HRed Giant LimitedMuheng Capital PartnersHong Kong LimitedDCP Capital Partners, L.P.Red Giant LimitedDCP General Partner, LtdDCP Capital Partners, L.P.DCP Partners LimitedDCP General Partner, LtdDCP, Ltd.DCP Partners LimitedJulian Juul WolhardtDCP, Ltd. 50%Muheng Capital PartnersHong Kong Limited (4)H441,011,443441,010,235H1,208 XV23336 V. (i) 2,846.02,558.0 (i)742.38(ii)714.05(iii)383.40(iv)255.80 1 KeystoneKeystoneTriGUARD3FDATriGUARD3KeystoneTriGUARD3FDA255.8 (ii) 18,500,000H1,173.01,034.01 (i)471.30(ii)562.71 (iii) 18,042,500H1,4271,191.00986.81 * 1,4271,191.00 VI. 44,101,023HH10%4,410,102H (i) (ii) (iii)(a)(b)(c) (a)H(b)H5(c)H H HH10%H HH1%H H12H1% 12HH0.1% VII. VIII. IX. X. (1) (i)(ii) 13.1413.15A (i)(ii)(iii) (2) (i) (ii) AAA (ii) (iii) (i)(ii)(iii) (iv) (v) D.1.2 (i) (ii) A D.1.2 (iii) (iv) (i) 1.14.0714.33 2. 3.(i)(ii)(iii) 4. 5. 6.A (ii) 1.(a)(x)(y)A(b)2410(a)(b) a. b.IX.39 c.3438 d. e. f. g. h. i. 2.D.1.23.08XI.D.1.23.08 XI. D.1.2 D.1.23.08 (i)(ii)(iii)D.1.2D.1.2 3.08 (i) (ii)(iii)D.1.23.08 D.1.2 XII. XIII. (i) 1.2. (ii) (iii) 13.51B(1) 1. (iv) 1.2. (v) II. XIV. 1. 8823311 2. 34 3. 4. 5. 6. 7. 25%15%15% 23%23% 21%21% 7. 19%19% 19%15%